Idecabtagene vicleucel
- Generic Name
- Idecabtagene vicleucel
- Brand Names
- Abecma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 8PX1X7UG4D
- Background
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal an...
- Indication
Idecabtagene vicleucel is indicated to treat adult patients with relapsed or refractory multiple myeloma who have tried at least 4 other lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 monoclonal antibody.
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT06698887
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeonranamdo, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT06357754
- Locations
- 🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
🇩🇪Universitaetsklinikum Essen (AoR), Essen, Germany
🇯🇵Kumamoto University, Kumamoto-city, Kumamoto, Japan
Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT06154902
- Locations
- 🇫🇷
DESCAR-T Registry, Paris, France
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 618
- Registration Number
- NCT06045806
- Locations
- 🇺🇸
Local Institution - 0147, Columbus, Ohio, United States
🇺🇸Local Institution - 0102, Boston, Massachusetts, United States
🇩🇪Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.